NRA Capital Pte Ltd
Sienna Cancer Diagnostics Limited (ASX: SDX) - IVD Test for Bladder Cancer - Distribution Agreements in the US & Europe(Image)

Sienna Cancer Diagnostics Limited (ASX: SDX) - IVD Test for Bladder Cancer - Distribution Agreements in the US & Europe

Equity Research Coverage Reports

We have determined a base case valuation for SDX of $0.31 per share. The valuation incorporates a number of assumptions regarding the sales of the IVD product for the detection of bladder cancer in the US and Europe. The product has been de-risked to a large extent given the company has obtained an IVD classification in the US, Europe and Australia.

More company reports


Access to this Web site is granted by NRA Capital Pte. Ltd. strictly on the terms and subject to the conditions set out hereunder. By entering into the Web Site, Subscriber is deemed to have accepted and agreed to be bound by the terms and conditions  set out hereunder.